Perspective Therapeutics (CATX) Share-based Compensation (2010 - 2026)
Perspective Therapeutics (CATX) posted Share-based Compensation of $2.6 million for Q1 2026, up 10.57% sequentially from $2.3 million in Q4 2025, and up 21.69% YoY from $2.1 million in Q1 2025.
Perspective Therapeutics (CATX) Share-based Compensation (2010 - 2026) Analysis & Trends
Perspective Therapeutics has reported Share-based Compensation for 17 years, with the latest figure at $2.6 million in Q1 2026.
- Quarterly Share-based Compensation rose 21.69% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.4 million (up 40.67% YoY) and the FY2025 annual result came in at $21.3 million, down 10.13% from the prior year.
- Share-based Compensation rose to $2.6 million in Q1 2026 per CATX's latest filing, from $2.3 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $2.6 million in Q1 2026 and troughed at $125000.0 in Q4 2023.
- A 5-year average of $1.2 million and a median of $982000.0 in 2023 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2024: Share-based Compensation sank 74.8% in 2023, then soared 1548.0% in 2024.
- Over 5 years, Share-based Compensation stood at $496000.0 in 2022, then plunged by 74.8% to $125000.0 in 2023, then jumped by 1548.0% to $2.1 million in 2024, then increased by 12.09% to $2.3 million in 2025, then climbed by 10.57% to $2.6 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $2.6 million, $2.3 million, and $2.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.59 Bn | 193.99 Bn | 7.27 Bn | 168.00 Mn |
| 2 | Stryker | 126.90 Bn | 123.42 Bn | 4.50 Bn | 7.00 Mn |
| 3 | Medtronic | 118.28 Bn | 109.06 Bn | 6.41 Bn | 95.00 Mn |
| 4 | Boston Scientific | 72.95 Bn | 72.41 Bn | 3.85 Bn | 87.00 Mn |
| 5 | Edwards Lifesciences | 51.59 Bn | 47.34 Bn | 1.35 Bn | 42.20 Mn |
| 6 | Dexcom | 34.36 Bn | 32.41 Bn | 830.00 Mn | 39.00 Mn |
| 7 | GE HealthCare Technologies | 33.64 Bn | 31.53 Bn | 2.18 Bn | 45.00 Mn |
| 8 | Koninklijke Philips | 26.08 Bn | 22.76 Bn | 4.55 Bn | 94.15 Mn |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 12.80 Mn |
| 10 | Perspective Therapeutics | 401.77 Mn | 401.77 Mn | - | 3.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.05 Mn |
| Jun 30, 2026 | 3.05 Mn |
| Mar 31, 2026 | 2.55 Mn |
| Mar 31, 2026 | 2.55 Mn |
| Dec 31, 2025 | 2.31 Mn |
| Dec 31, 2025 | 2.31 Mn |
| Sep 30, 2025 | 2.16 Mn |
| Sep 30, 2025 | 2.16 Mn |
| Jun 30, 2025 | 2.40 Mn |
| Jun 30, 2025 | 2.40 Mn |
| Mar 31, 2025 | 2.10 Mn |
| Mar 31, 2025 | 2.10 Mn |
| Dec 31, 2024 | 2.06 Mn |
| Dec 31, 2024 | 2.06 Mn |
| Sep 30, 2024 | 1.95 Mn |
| Sep 30, 2024 | 1.95 Mn |
| Jun 30, 2024 | 587,000.00 |
| Jun 30, 2024 | 587,000.00 |
| Mar 31, 2024 | 656,000.00 |
| Mar 31, 2024 | 656,000.00 |